© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
Isatuximab improved progression-free survival in a Phase III study.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Cabometyx is the third liver cancer drug approved in the past six months.
Venclexta alone or in combination with Rituxan improved progression-free survival in patients with chronic lymphocytic leukemia.
Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
Elzonris approved for bone marrow disease that can evolve into leukemia.
They are geared to the 10 to 15 percent of people with endometrial cancer who are diagnosed with an advanced stage of the disease.
Talazoparib slowed disease progression compared to chemotherapy in EMBRACA study.
Cancer world is full of ups and downs.
ORR, PFS, TTP…we help you sort out what they mean.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
